Impact of age on outcomes after transcatheter tricuspid valve edge-to-edge repair: insights from EuroTR.

IF 3.7 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Clinical Research in Cardiology Pub Date : 2025-09-23 DOI:10.1007/s00392-025-02702-8

Julia Novotny, Lukas Stolz, Karl-Patrik Kresoja, Jennifer von Stein, Vera Fortmeier, Christoph Pauschinger, Wolfgang Rottbauer, Mohammad Kassar, Bjoern Goebel, Paolo Denti, Paul Achouh, Tienush Rassaf, Manuel Barreiro-Perez, Peter Boekstegers, Andreas Rück, Monika Zdanyte, Marianna Adamo, Philipp M Doldi, Ludwig T Weckbach, Thomas J Stocker, Flavien Vincent, Philipp Schlegel, Sebastian Rosch, Mirjam G Wild, Christian Besler, Stefan Toggweiler, Stephanie Brunner, Julia Grapsa, Tiffany Patterson, Holger Thiele, Tobias Kister, Giuseppe Tarantini, Giulia Masiero, Marco De Carlo, Alessandro Sticchi, Fabian Voss, Amin Polzin, Antonio Popolo Rubbio, Francesco Bedogni, Mathias H Konstandin, Eric Van Belle, Marco Metra, Tobias Geisler, Rodrigo Estévez-Loureiro, Amir Abbas Mahabadi, Nicole Karam, Francesco Maisano, Philipp Lauten, Fabien Praz, Mirjam Kessler, Daniel Kalbacher, Volker Rudolph, Christos Iliadis, Philipp Lurz, Jörg Hausleiter

{"title":"Impact of age on outcomes after transcatheter tricuspid valve edge-to-edge repair: insights from EuroTR.","authors":"Julia Novotny, Lukas Stolz, Karl-Patrik Kresoja, Jennifer von Stein, Vera Fortmeier, Christoph Pauschinger, Wolfgang Rottbauer, Mohammad Kassar, Bjoern Goebel, Paolo Denti, Paul Achouh, Tienush Rassaf, Manuel Barreiro-Perez, Peter Boekstegers, Andreas Rück, Monika Zdanyte, Marianna Adamo, Philipp M Doldi, Ludwig T Weckbach, Thomas J Stocker, Flavien Vincent, Philipp Schlegel, Sebastian Rosch, Mirjam G Wild, Christian Besler, Stefan Toggweiler, Stephanie Brunner, Julia Grapsa, Tiffany Patterson, Holger Thiele, Tobias Kister, Giuseppe Tarantini, Giulia Masiero, Marco De Carlo, Alessandro Sticchi, Fabian Voss, Amin Polzin, Antonio Popolo Rubbio, Francesco Bedogni, Mathias H Konstandin, Eric Van Belle, Marco Metra, Tobias Geisler, Rodrigo Estévez-Loureiro, Amir Abbas Mahabadi, Nicole Karam, Francesco Maisano, Philipp Lauten, Fabien Praz, Mirjam Kessler, Daniel Kalbacher, Volker Rudolph, Christos Iliadis, Philipp Lurz, Jörg Hausleiter","doi":"10.1007/s00392-025-02702-8","DOIUrl":null,"url":null,"abstract":"Objective: Age stratified data regarding symptomatic and survival outcome of patients undergoing transcatheter tricuspid valve edge-to-edge repair (T-TEER) for severe tricuspid regurgitation (TR) are scarce. Aim of this study was to evaluate TR reduction, symptomatic outcomes, and survival following T-TEER stratified by patient age at intervention.Methods: Using data from the large European Registry of Transcatheter Repair for Tricuspid Regurgitation (EuroTR registry, NCT06307262) we investigated the impact of patient age at intervention on procedural TR reduction, clinical outcome according to New York Heart Association (NYHA) class at latest available follow-up and two-year survival as well as two-year survival free from hospitalization for heart failure (HHF).Results: The study included 2340 patients divided into four groups according to quartiles of age at intervention (1st quartile: 668 patients [69.9 ± 7.2 years] up to 4th quartile: 561 patients [86.2 ± 2.2 years]). Most common TR etiology in all groups was secondary TR with 83.6%-90.1%. TR reduction from baseline to discharge was similar in all groups (TR ≤2+ 77.3% 1st quartile, 82% 2nd quartile, 79.5% 3rd quartile and 82.8% 4th quartile, p = 0.085). TR severity at follow-up was also comparable (TR ≤2+ 68.1% 1st quartile, 72.1% 2nd quartile, 76.7% 3rd quartile and 73.7% 4th quartile, p = 0.135). Regarding NYHA class patients in all groups benefited equally. Overall two-year survival and two-year survival free from HHF after intervention did not differ between age groups.Conclusions: T-TEER effectively reduces TR in elderly patients. Irrespective of age, patients showed symptomatic benefit and comparable two-year survival free from HHF.","PeriodicalId":10474,"journal":{"name":"Clinical Research in Cardiology","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Research in Cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00392-025-02702-8","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Age stratified data regarding symptomatic and survival outcome of patients undergoing transcatheter tricuspid valve edge-to-edge repair (T-TEER) for severe tricuspid regurgitation (TR) are scarce. Aim of this study was to evaluate TR reduction, symptomatic outcomes, and survival following T-TEER stratified by patient age at intervention.

Methods: Using data from the large European Registry of Transcatheter Repair for Tricuspid Regurgitation (EuroTR registry, NCT06307262) we investigated the impact of patient age at intervention on procedural TR reduction, clinical outcome according to New York Heart Association (NYHA) class at latest available follow-up and two-year survival as well as two-year survival free from hospitalization for heart failure (HHF).

Results: The study included 2340 patients divided into four groups according to quartiles of age at intervention (1st quartile: 668 patients [69.9 ± 7.2 years] up to 4th quartile: 561 patients [86.2 ± 2.2 years]). Most common TR etiology in all groups was secondary TR with 83.6%-90.1%. TR reduction from baseline to discharge was similar in all groups (TR ≤2+ 77.3% 1st quartile, 82% 2nd quartile, 79.5% 3rd quartile and 82.8% 4th quartile, p = 0.085). TR severity at follow-up was also comparable (TR ≤2+ 68.1% 1st quartile, 72.1% 2nd quartile, 76.7% 3rd quartile and 73.7% 4th quartile, p = 0.135). Regarding NYHA class patients in all groups benefited equally. Overall two-year survival and two-year survival free from HHF after intervention did not differ between age groups.

Conclusions: T-TEER effectively reduces TR in elderly patients. Irrespective of age, patients showed symptomatic benefit and comparable two-year survival free from HHF.

查看原文本刊更多论文

年龄对经导管三尖瓣边缘到边缘修复后结果的影响：来自EuroTR的见解

目的：关于接受经导管三尖瓣边缘到边缘修复（T-TEER）治疗严重三尖瓣反流（TR）患者的症状和生存结果的年龄分层数据很少。本研究的目的是评估按患者年龄分层T-TEER干预后的TR减少、症状结局和生存率。方法：使用来自欧洲经导管修复三尖瓣反流大型注册中心（EuroTR Registry, NCT06307262）的数据，我们调查了干预时患者年龄对程序性TR降低的影响，根据最新随访的纽约心脏协会（NYHA）分类的临床结果，以及两年生存率和两年无心力衰竭住院生存率（HHF）。结果：研究纳入2340例患者，按干预时年龄四分位数分为四组（第一四分位数：668例患者[69.9±7.2岁]至第四四分位数：561例患者[86.2±2.2岁]）。所有组中最常见的TR病因为继发性TR，占83.6% ~ 90.1%。各组从基线到出院的TR降低率相似（TR≤2+ 77.3%第1四分位数，82%第2四分位数，79.5%第3四分位数和82.8%第4四分位数，p = 0.085）。随访时TR严重程度也具有可比性（TR≤2+第1四分位数68.1%，第2四分位数72.1%，第3四分位数76.7%，第4四分位数73.7%,p = 0.135）。对于NYHA级患者，所有组均受益。干预后总的两年生存率和无HHF的两年生存率在年龄组之间没有差异。结论：T-TEER可有效降低老年患者的TR。无论年龄大小，患者均表现出症状性获益和无HHF的两年生存率相当。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Research in Cardiology 医学-心血管系统

CiteScore

11.40

自引率

4.00%

发文量

140

审稿时长

4-8 weeks

期刊介绍： Clinical Research in Cardiology is an international journal for clinical cardiovascular research. It provides a forum for original and review articles as well as critical perspective articles. Articles are only accepted if they meet stringent scientific standards and have undergone peer review. The journal regularly receives articles from the field of clinical cardiology, angiology, as well as heart and vascular surgery. As the official journal of the German Cardiac Society, it gives a current and competent survey on the diagnosis and therapy of heart and vascular diseases.